白癜風(fēng)患者CLEC-2BmRNA表達及其與臨床相關(guān)性研究
發(fā)布時間：2019-04-26 18:28
【摘要】：目的 探討CLEC-2B (C-type lectin domain family 2, member B)基因在白癜風(fēng)患者外周血與皮損中的表達與疾病臨床類型、病程、病期、轉(zhuǎn)歸的相關(guān)性,并進行皮損區(qū)CLEC-2B基因的蛋白表達,以明確CLEC-2B基因表達的細胞定位。通過本實驗發(fā)現(xiàn)疾病多樣性及臨床轉(zhuǎn)歸與基因差異表達的相關(guān)性,據(jù)此預(yù)測白癜風(fēng)發(fā)生、臨床分型、分期及預(yù)后,從而對臨床起到一定的指導(dǎo)作用。 方法 應(yīng)用反轉(zhuǎn)錄-聚合酶鏈式反應(yīng)(reverse transcription-polymerase chain reaction, RT-PCR)方法,對白癜風(fēng)患者及正常對照者外周血及皮膚組織中CLEC-2B的表達量進行分析,擴增產(chǎn)物經(jīng)4.0%瓊脂糖溴乙錠電泳,凝膠成像儀下攝像證實。按照白癜風(fēng)的診斷標準,利用統(tǒng)計軟件分析不同臨床類型、不同病期、不同病程、不同轉(zhuǎn)歸的白癜風(fēng)皮損區(qū)、外周血及正常人皮膚、外周血CLEC-2B基因表達的差異。并對白癜風(fēng)患者皮損組織與正常皮膚組織,用免疫組織化學(xué)方法確定皮膚組織中CLEC-2B基因的蛋白表達。 結(jié)果 1.白癜風(fēng)患者組皮損中CLEC-2BmRNA表達量高于正常對照組,差異有統(tǒng)計學(xué)意義(t=2.581,P0.05)。 2.白癜風(fēng)患者與正常對照組外周血中CLEC-2BmRNA的表達量比較差異無統(tǒng)計學(xué)意義(t=1.375,P0.05)。 3.不同性別白癜風(fēng)患者皮損組中CLEC-2BmRNA表達量比較無統(tǒng)計學(xué)差異(t=1.341,P0.05)。 4.不同病程白癜風(fēng)患者皮損中CLEC-2BmRNA的表達量比較差異無統(tǒng)計學(xué)意義(F=1.479,P0.05)。 5.尋常型白癜風(fēng)皮損組中CLEC-2BmRNA的表達量高于節(jié)段型白癜風(fēng)組,差異有統(tǒng)計學(xué)意義(t=2.432,P0.05)。 6.進展期白癜風(fēng)患者組皮損中CLEC-2BmRNA的表達量高于穩(wěn)定期患者組,差異有統(tǒng)計學(xué)意義(t=2.204,P0.05)。 7.在不同轉(zhuǎn)歸的白癜風(fēng)患者中,各組皮損中CLEC-2B mRNA的表達量差別有統(tǒng)計學(xué)意義(F=5.218,P0.05)。 8.通過免疫組織化學(xué)方法證實在白癜風(fēng)皮損真皮層中的淋巴細胞中有CLEC-2B蛋白的表達。 結(jié)論 1.白癜風(fēng)患者皮損中CLEC-2B的表達水平的增高,提示CLEC-2B在白癜風(fēng)發(fā)病機制中具有一定的意義。 2.白癜風(fēng)患者進展期CLEC-2B的表達水平高于穩(wěn)定期患者,提示CLEC-2B與白癜風(fēng)病期進展有關(guān)。 3. CLEC-2B在尋常型白癜風(fēng)的表達水平高于節(jié)段型白癜風(fēng),提示CLEC-2B在決定白癜風(fēng)的分型中起一定的作用,同時推測CLEC-2B可能參與白癜風(fēng)的免疫機制。 4.不同轉(zhuǎn)歸的白癜風(fēng)患者CLEC-2B的表達水平差異有統(tǒng)計學(xué)意義,從而在基因水平揭示同一疾病不同轉(zhuǎn)歸的謎底,指導(dǎo)臨床診斷和預(yù)后。同時為尋找調(diào)控該基因的藥物,改善疾病轉(zhuǎn)歸奠定基礎(chǔ)。 5. CLEC-2B蛋白表達于白癜風(fēng)患者皮損真皮層淋巴細胞的細胞核中,進一步加深了對本基因的認識。
[Abstract]:Objective to investigate the expression of CLEC-2B (C-type lectin domain family-2, member B) gene in peripheral blood and lesions of patients with vitiligo and its correlation with clinical type, course of disease, stage of disease and prognosis. The protein expression of CLEC-2B gene was carried out to identify the cellular localization of CLEC-2B gene expression. In this study, we found the correlation between disease diversity and clinical outcome and gene differential expression, so as to predict the occurrence, clinical classification, staging and prognosis of vitiligo, and thus play a guiding role in clinical practice. Methods reverse transcription polymerase chain reaction (reverse transcription-polymerase chain reaction, RT-PCR) was used to analyze the expression of CLEC-2B in peripheral blood and skin of patients with vitiligo and normal controls. The amplified products were confirmed by 4.0% agarose bromide ethidium electrophoresis. According to the diagnostic criteria of vitiligo, statistical software was used to analyze the difference of CLEC-2B gene expression in different clinical types, different disease stages, different course of disease, different prognosis of vitiligo skin, peripheral blood and normal skin, and peripheral blood. The protein expression of CLEC-2B gene in the skin tissue of patients with vitiligo and normal skin tissue was determined by immunohistochemical method. Outcome 1. The expression of CLEC-2BmRNA in the lesions of patients with vitiligo was significantly higher than that of normal controls (t = 2.581, P0.05). 2. There was no significant difference in the expression of CLEC-2BmRNA in peripheral blood between vitiligo patients and normal controls (t = 1.375, P0.05). 3. There was no significant difference in the expression of CLEC-2BmRNA between male and female patients with vitiligo (t = 1.341, P0.05). 4. There was no significant difference in the expression of CLEC-2BmRNA in the lesions of patients with vitiligo at different stages (F = 1.479, P0.05). 5. The expression of CLEC-2BmRNA in vitiligo vulgaris group was higher than that in segmental vitiligo group (t = 2.432, P0.05). 6. The expression of CLEC-2BmRNA in skin lesions of patients with progressive vitiligo was significantly higher than that of patients with stable vitiligo (t = 2.204, P0.05). 7. In the patients with vitiligo with different outcomes, the expression of CLEC-2B mRNA in the lesions of each group was significantly different (F = 5.218, P0.05). 8. The expression of CLEC-2B protein was confirmed by immunohistochemical method in the lymphocytes of the dermis of vitiligo. Conclusion 1. The increased expression of CLEC-2B in the lesions of patients with vitiligo suggests that CLEC-2B may play an important role in the pathogenesis of vitiligo. 2. The expression level of CLEC-2B in patients with advanced vitiligo was higher than that in patients with stable vitiligo, suggesting that CLEC-2B was related to the progression of vitiligo. 3. The expression level of CLEC-2B in vitiligo vulgaris is higher than that in segmental vitiligo, suggesting that CLEC-2B may play a role in determining the classification of vitiligo, and that CLEC-2B may be involved in the immune mechanism of vitiligo. 4. The expression level of CLEC-2B in vitiligo patients with different prognosis has statistical significance, so as to reveal the mystery of different outcomes of the same disease at the gene level, and guide the clinical diagnosis and prognosis. At the same time, it lays a foundation for finding the drugs that regulate the gene and improving the prognosis of the disease. 5. The expression of CLEC-2B protein in the nuclei of dermis lymphocytes from patients with vitiligo further enhanced the understanding of this gene.
【學(xué)位授予單位】：天津醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2011
【分類號】：R758.41
本文編號：2466293
[Abstract]:Objective to investigate the expression of CLEC-2B (C-type lectin domain family-2, member B) gene in peripheral blood and lesions of patients with vitiligo and its correlation with clinical type, course of disease, stage of disease and prognosis. The protein expression of CLEC-2B gene was carried out to identify the cellular localization of CLEC-2B gene expression. In this study, we found the correlation between disease diversity and clinical outcome and gene differential expression, so as to predict the occurrence, clinical classification, staging and prognosis of vitiligo, and thus play a guiding role in clinical practice. Methods reverse transcription polymerase chain reaction (reverse transcription-polymerase chain reaction, RT-PCR) was used to analyze the expression of CLEC-2B in peripheral blood and skin of patients with vitiligo and normal controls. The amplified products were confirmed by 4.0% agarose bromide ethidium electrophoresis. According to the diagnostic criteria of vitiligo, statistical software was used to analyze the difference of CLEC-2B gene expression in different clinical types, different disease stages, different course of disease, different prognosis of vitiligo skin, peripheral blood and normal skin, and peripheral blood. The protein expression of CLEC-2B gene in the skin tissue of patients with vitiligo and normal skin tissue was determined by immunohistochemical method. Outcome 1. The expression of CLEC-2BmRNA in the lesions of patients with vitiligo was significantly higher than that of normal controls (t = 2.581, P0.05). 2. There was no significant difference in the expression of CLEC-2BmRNA in peripheral blood between vitiligo patients and normal controls (t = 1.375, P0.05). 3. There was no significant difference in the expression of CLEC-2BmRNA between male and female patients with vitiligo (t = 1.341, P0.05). 4. There was no significant difference in the expression of CLEC-2BmRNA in the lesions of patients with vitiligo at different stages (F = 1.479, P0.05). 5. The expression of CLEC-2BmRNA in vitiligo vulgaris group was higher than that in segmental vitiligo group (t = 2.432, P0.05). 6. The expression of CLEC-2BmRNA in skin lesions of patients with progressive vitiligo was significantly higher than that of patients with stable vitiligo (t = 2.204, P0.05). 7. In the patients with vitiligo with different outcomes, the expression of CLEC-2B mRNA in the lesions of each group was significantly different (F = 5.218, P0.05). 8. The expression of CLEC-2B protein was confirmed by immunohistochemical method in the lymphocytes of the dermis of vitiligo. Conclusion 1. The increased expression of CLEC-2B in the lesions of patients with vitiligo suggests that CLEC-2B may play an important role in the pathogenesis of vitiligo. 2. The expression level of CLEC-2B in patients with advanced vitiligo was higher than that in patients with stable vitiligo, suggesting that CLEC-2B was related to the progression of vitiligo. 3. The expression level of CLEC-2B in vitiligo vulgaris is higher than that in segmental vitiligo, suggesting that CLEC-2B may play a role in determining the classification of vitiligo, and that CLEC-2B may be involved in the immune mechanism of vitiligo. 4. The expression level of CLEC-2B in vitiligo patients with different prognosis has statistical significance, so as to reveal the mystery of different outcomes of the same disease at the gene level, and guide the clinical diagnosis and prognosis. At the same time, it lays a foundation for finding the drugs that regulate the gene and improving the prognosis of the disease. 5. The expression of CLEC-2B protein in the nuclei of dermis lymphocytes from patients with vitiligo further enhanced the understanding of this gene.
【學(xué)位授予單位】：天津醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2011
【分類號】：R758.41
【參考文獻】
相關(guān)期刊論文 前10條
1 張啟國;方春紅;曾靜;羅芳;徐世正;姚瑩;張璃;;尋常型進展期白癜風(fēng)患者外周血T淋巴細胞Fas和FasL的表達[J];臨床皮膚科雜志;2006年03期
2 李凱;高琳;楊勵;齊顯龍;李春英;高天文;;COMT基因單核苷酸多態(tài)性與漢族白癜風(fēng)發(fā)病的相關(guān)性[J];中國美容醫(yī)學(xué);2007年03期
3 王梁燕,洪奇華,張耀洲;實時定量PCR技術(shù)及其應(yīng)用[J];細胞生物學(xué)雜志;2004年01期
4 王丹妮;權(quán)晟;袁鋒;張麟;左先波;孫良丹;楊森;張學(xué)軍;;COMT基因遺傳多態(tài)性與漢族人白癜風(fēng)易感性關(guān)聯(lián)分析[J];安徽醫(yī)科大學(xué)學(xué)報;2009年03期
5 張麟;袁鋒;王丹妮;王培光;孫良丹;張學(xué)軍;楊森;;CTLA4基因多態(tài)性與漢族人白癜風(fēng)易感性相關(guān)分析[J];安徽醫(yī)科大學(xué)學(xué)報;2009年03期
6 袁鋒;權(quán)晟;王丹妮;張麟;左先波;孫良丹;楊森;張學(xué)軍;;PTPN22基因多態(tài)性與漢族人白癜風(fēng)易感性關(guān)聯(lián)分析[J];安徽醫(yī)科大學(xué)學(xué)報;2009年03期
7 王巖,肖毅,張曉東,趙玉銘,劉永學(xué),宋芳吉,陳洪鐸;有無家族史白癜風(fēng)與HLA-Ⅰ類抗原的關(guān)聯(lián)性研究[J];中國皮膚性病學(xué)雜志;2001年03期
8 肖毅,趙玉銘,宋芳吉,劉永學(xué),高德凱,楊克力;HLA-DRB1等位基因與中國北方漢族 白癜風(fēng)的相關(guān)性[J];中華皮膚科雜志;2000年01期
9 李志強,劉榮卿,高天文,趙小東,陳金穆;白癜風(fēng)患者血清中抗黑素細胞膜表面抗原自身抗體的檢測[J];中華皮膚科雜志;2001年04期
10 程東慶,許愛娥,劉紅焱,鮑建芳,沈建根,邵傳森;白癜風(fēng)患者外周血T淋巴細胞、自然殺傷細胞功能的研究[J];中華皮膚科雜志;2001年06期
相關(guān)碩士學(xué)位論文 前1條
1 唐果;CTLA-4基因單核苷酸多態(tài)性與白癜風(fēng)相關(guān)性研究[D];第四軍醫(yī)大學(xué);2007年
，本文編號：2466293
本文鏈接：http://www.sikaile.net/yixuelunwen/pifb/2466293.html
最近更新
教材專著
